Dabrafenib
Solid Tumour
Cancer Research UKSmall moleculePhase 2/3Active
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 89/ 100
Competitive context
17 Active assets in the Solid Tumour cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Atezolizumab Genentech, Inc. | Phase 2/3 | B |
DEXAMETHASONE Henlix, Inc | Phase 2 | B |
ALECTINIB Cancer Research UK | Phase 2/3 | B |
Entrectinib Cancer Research UK | Phase 2/3 | B |
gsk1120212 Cancer Research UK | Phase 2/3 | B |
View all 36 →
Same molecule, other indications
Dabrafenib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →